Novartis Ag

Ciba Specialty Chemicals Corporation

Ciba-geigy Corporation

Novartis Animal Health Us, Inc.

Zyma Sa

Basf Se Corporation

Erwin Marti

Andreas Burkhard

Josef Zelger

Peter Rohringer

Werner Schreiber

Wolfgang Marterer

Hans Rudolf Oswald

Andre Geoffroy

Thomas Ehlis

Hiroshi Nakagawa

Isamu Utsumi

Peter Buehlmayer

Andr&eacute; Geoffroy

Karlheinz Franke

Koichi Akimoto

Gustave Huber

Alexandre Gumma

Oskar Heiber

Tatsuhiko Miyata

Andr&eacute; Joseph Geoffroy

Peter Bühlmayer

Walter Oechslein

André Geoffroy

The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.

Valsartan salts

The invention relates to new forms of salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.

Salt hydrates

Crystalline salt forms of valsartan

The present invention provides a hydrate of the 4,4&prime;-di-triazinylamino-2,2&prime;-di-sulfostilbene compound having the formula:

Triazinylaminostilbene compounds

The present invention relates to several new, polymorphous crystal forms of Dicyclanil, and hydrates and solvates thereof, as well as the preparation thereof. In particular, the invention relates to substantially pure crystal forms of Dicyclanil, having characteristic lattice structures, which are effective for the control of insects and ectoparasites.

Dicyclanil polymorphs and hydrates and their preparation

The present invention provides a hydrate of the 4,4'-di-triazinylamino-2,2'-di-sulfostilbene compound having the formula: ##STR1## in which M and M.sub.1 independently represent hydrogen, an alkaline-, an alkaline earth metal or ammonium, x is a number within the range of from 1 to 30, and the crystal form of the hydrate (I) being characterized by an X-ray diffraction pattern which is essentially as set out in the accompanying FIGS. 1 to 11; or a mixture containing one or more of the hydrates of the 4,4'-di-triazinylamino-2,2'-di-sulfostilbene compound having the formula (I); processes for the preparation of the new hydrates; and the use of the new hydrates for the preparation of concentrated aqueous formulations of fluorescent whitening agents.

The present invention relates to novel hydrates of the disodium salt or dipotassium salt of 4,4'-bis(2-sulfostyryl)biphenyl characterized by their water of hydration content, to the crystal forms associated therewith, characterized by their X-ray diffraction pattern, to processes for the preparation, and to their use for the preparation of concentrated formulations of fluorescent whitening agents.

Hydrates of the disodium salt or dipotassium salt of

Novel crystal modifications of (+)-catechin monohydrate and of (+)-catechin anhydrate more suitable for pharmaceutical preparations for reasons of higher stability against moisture and/or light and distinguished from hitherto known modifications by unique X-ray diffraction spectra are produced by specific recrystallization and/or crystal rearrangement processes and pharmaceutical preparations comprising the novel crystal forms.

Crystal modifications of (+)-catechin and pharmaceutical preparations

Growing community of inventors

Basel, Switzerland

Erwin Marti